Effects of BRS and LRS on Postoperative Acute Kidney Injury

Acute Kidney Injury Clinical Trial

— BRS/LRS  

Official title:

Effects of Sodium Bicarbonate Ringer's Injection and Sodium Lactated Ringer's Injection on Postoperative Acute Kidney Injury in Patients Undergoing Major Abdominal Surgery: a Randomized, Controlled, Open-label Clinical Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04835038
• Other study ID #: ChiCTR2100044465
• Status: Recruiting
• Phase: Phase 4
• Start date: June 1, 2021
• Est. completion date: August 2023

Study information

• Verified date: April 2023
• Source: Tongji Hospital
• Contact: Shiyong Li
• Phone: 18062154189
• Email: shiyongli[@]hust.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

1. Title: Effects of Sodium Bicarbonate Ringer's Injection and Sodium Lactated Ringer's Injection on postoperative acute kidney injury in patients undergoing major abdominal surgery: a randomized, controlled, open-label clinical study 2. Objective: To evaluate the effect of BRS and LRS infusion on acute renal injury in patients undergoing major abdominal surgery 3. Primary outcome: Incidence of AKI at 28 days postoperative (defined as acute kidney injury, according to Kidgo 2012 definition and classification). 4. Study Design: Randomized, controlled, open-label clinical study.

Description:

1. Subjects: patients who planned to undergo elective major abdominal surgery. 2. Study data collection period: Subjects signed the consent form until 28 days after discharge or died in hospital or withdrew from the study. 3. Number of research centers/sample size: 3400 patients were planned to be included. 4. Study process: Among patients undergoing elective surgery, the researchers will include patients who meet the inclusion criteria for elective major abdominal surgery and agree to participate in the study. The data to be collected in this study will be recorded by the researcher in the eCRF, including: (1) Data to be collected during the screening period and preoperatively: patients' basic characteristics and demographic data (2) Data to be recorded during and/or after surgery: primary study indicators, secondary indicators, and other indicators.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3400
• Est. completion date: August 2023
• Est. primary completion date: June 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 70 Years

Eligibility

Inclusion Criteria:

1. ASA grade ?-?.

2. patients aged between 20 and 70, signed informed consent form, and are willing to participate in the study.

3. BMI = 30kg/m2.

4. elective major abdominal surgery for the first time (radical resection of ovarian cancer, radical resection of cervical cancer, radical resection of gastric cancer, radical resection of colorectal cancer, radical resection of bladder tumor and radical resection of prostate tumor).

5. NYHA cardiac function grade ?-?.

6. the function of liver and kidney is normal before operation.

7. the blood coagulation function was normal before operation.

8. hemoglobin > 70g/L.

9. sinus rhythm was detected by electrocardiogram and there were no other malignant arrhythmias.

Exclusion Criteria:

1. Emergency surgery.

2. liver and kidney surgery.

3. complicated with chronic respiratory diseases and FEV1/FVC < 70%.

4. the operation time is less than 2 hours.

5. patients with mental illness or cognitive impairment.

6. uncontrolled hypertension with blood pressure higher than 180 × 100mmHg.

7. patients with hypothyroidism.

8. pregnant or lactating patients. -

Related Conditions & MeSH terms

• Acute Kidney Injury
• Wounds and Injuries

Intervention

Drug:
• Sodium Bicarbonate Ringer's Injection
Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)
• Sodium Lactated Ringer's Injection
Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)

Locations

Country	Name	City	State
China	Tongji hospital	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Tongji Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Postoperative acute renal injury	The incidence of AKI at 28 days after surgery (Acute kidney injury is defined and graded according to KIDGO 2012)	28 days after surgery